{"ticker": {"uuid": "6458fb74-86d0-4241-833b-0a5ee9f2a32b", "symbol": "MOLN", "name": "Molecular Partners AG ADR", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Molecular Partners Doses First Patients in Phase 2 Study of Biliary Tract Cancer Therapy", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/molecular-partners-doses-first-patients-073420686.html", "source_name": "MT Newswires", "published_at": "2026-07-16T07:34:20+00:00", "published_display": "16 Jul 2026 07:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Molecular Partners Announces Clinical Progress in Phase 2 TACTIC Combination Trial of MP0317 for Patients with Cholangiocarcinoma", "summary": "Molecular Partners has announced clinical progress in its Phase 2 TACTIC trial for MP0317, a drug for advanced biliary tract carcinoma (cholangiocarcinoma). The randomized study, combining MP0317 with chemoimmunotherapy, is actively recruiting patients across nine sites in France", "url": "https://www.manilatimes.net/2026/07/16/tmt-newswire/globenewswire/molecular-partners-announces-clinical-progress-in-phase-2-tactic-combination-trial-of-mp0317-for-patients-with-cholangiocarcinoma/2385574", "source_name": "The Manila Times", "published_at": "2026-07-16T05:11:23", "published_display": "16 Jul 2026 05:11", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Molecular Partners Showcases Bispecific Radio-DARPins at Gordon Research Conference", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/molecular-partners-showcases-bispecific-radio-050000390.html", "source_name": "GlobeNewswire", "published_at": "2026-07-15T05:00:00+00:00", "published_display": "15 Jul 2026 05:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Molecular Partners Highlights Bispecific Radio-DARPin Approach to Target Tumor Heterogeneity in Cancer", "summary": "Molecular Partners presented its bispecific Radio-DARPin approach to target tumor heterogeneity in cancer at the Gordon Research Conference. This innovative method aims to enhance radioligand therapy (RLT) by simultaneously engaging multiple tumor markers, thereby improving treat", "url": "https://www.quiverquant.com/news/Molecular+Partners+Highlights+Bispecific+Radio-DARPin+Approach+to+Target+Tumor+Heterogeneity+in+Cancer", "source_name": "Quiver Quantitative", "published_at": "2026-07-15T04:43:54", "published_display": "15 Jul 2026 04:43", "sentiment": "positive", "sentiment_pct": 82, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Molecular Partners Develops Two-Target Cancer Radiopharmaceuticals", "summary": "Molecular Partners presented new data on its bispecific and multispecific Radio-DARPins at the Gordon Research Conference on Radionuclide Theranostics for the Management of Cancer. The company is developing these Radio-DARPins to address tumor heterogeneity and engage multiple ca", "url": "https://www.stocktitan.net/news/MOLN/molecular-partners-showcases-bispecific-radio-dar-pins-at-gordon-6qs9gd3l9t6w.html", "source_name": "Stock Titan", "published_at": "2026-07-15T04:43:54", "published_display": "15 Jul 2026 04:43", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "European Penny Stocks To Watch In July 2026", "summary": "This article identifies three European penny stocks (Piquadro, GiG Software, and Molecular Partners) with potential for investors seeking growth opportunities beyond mainstream markets. It highlights their financial health, market performance, and strategic initiatives, noting bo", "url": "https://simplywall.st/stocks/ch/pharmaceuticals-biotech/vtx-moln/molecular-partners-shares/news/european-penny-stocks-to-watch-in-july-2026-1/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-09T05:39:59", "published_display": "09 Jul 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Molecular Partners (MOLN) Gains 2.25% as Buyers Test Resistance Near $4.29 - AD Line Divergence", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxPVXJVTFY0SzJWWnRJS2xwd01OMUhlUy1iSnc3QTRaOFhyQkljTG1idXhSSU52TGp2cEJPSVpfMHU5RFdxTHdYcTgwb2VKWkk2WGFmdDctTm94V1dZY0N5dkFTTWZKUUE1dUdiRGpfR2UwLVE5bGVnVnBBLU5RZ0loc2tjZHJpZ2c1aTZPTExjYXQxblF0MUF1SVpXM193cVQ1MHhIRXJVbXdOU3E1Vmo4clZB?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-08T01:41:33+00:00", "published_display": "08 Jul 2026 01:41", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Molecular Partners (NASDAQ: MOLN) details progress in Radio-DARPin cancer pipeline", "summary": "Molecular Partners (MOLN) provided an update on its Radio-DARPin pipeline for cancer treatment, announcing that its lead candidate, MP0712, is in an ongoing Phase 1/2a trial with initial data expected soon and comprehensive results in 2027. The company also highlighted a compassi", "url": "https://www.stocktitan.net/sec-filings/MOLN/6-k-molecular-partners-ag-current-report-foreign-issuer-cdb1a8ba4a33.html", "source_name": "Stock Titan", "published_at": "2026-07-07T10:09:30", "published_display": "07 Jul 2026 10:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Molecular Partners advances MP0712 cancer trial", "summary": "Molecular Partners has reported pipeline progress in its radiopharmaceutical programs, including active patient dosing in a Phase 1/2a trial for MP0712, targeting DLL3-positive small cell lung cancer and neuroendocrine tumors. Initial clinical data for MP0712 is anticipated in th", "url": "https://grafa.com/en/news/united-states/molecular-partners-radio-darpin-mp0712-clinical-trial", "source_name": "grafa.com", "published_at": "2026-07-06T13:11:03", "published_display": "06 Jul 2026 13:11", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Molecular Partners stock rating on trial progress By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxPVy1COEpJTTJWS0lDTGhTcUhaUy05RVBtZ3dlYWd1cTRrRl9ZTUs4NUdLUjVqeWo0ZmlvaVkzMG1sQ2NfR3hnalFESEhOM2d1eWFfUWZjbk9SbEZtSWNsbHg3dXNRVFBia0FyRVE2em9DTm5DR2wyVkhId05zUUpxMFdKUElyc05uRklMREs1dDhUeUtkSkthbEh2ZFhxZzZHTnJXc0lTem96dDR0M2VTeEthVTZ5Z3pMMDAxazlROXR2bVM0ZmpfbFBHcTBHUjlX?oc=5", "source_name": "Investing.com South Africa", "published_at": "2026-07-06T12:03:39+00:00", "published_display": "06 Jul 2026 12:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Molecular Partners stock rating on trial progress", "summary": "H.C. Wainwright has reiterated a Buy rating and a $13.00 price target for Molecular Partners (NASDAQ:MOLN) following progress in its clinical trials. The company recently announced the first patient dosing in a Phase 1/2a trial for MP0712, a DLL3-targeted Radio-DARPin for small c", "url": "https://www.investing.com/news/analyst-ratings/hc-wainwright-reiterates-molecular-partners-stock-rating-on-trial-progress-93CH-4776192", "source_name": "Investing.com", "published_at": "2026-07-06T12:11:04", "published_display": "06 Jul 2026 12:11", "sentiment": "positive", "sentiment_pct": 76, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Molecular Partners Makes Progress on Radiotherapy Cancer Candidates", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/molecular-partners-makes-progress-radiotherapy-095132431.html", "source_name": "MT Newswires", "published_at": "2026-07-06T09:51:32+00:00", "published_display": "06 Jul 2026 09:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Molecular Partners Updates on Clinical Progress Across Expanding Pipeline of DARPin Radiotherapeutics", "summary": "Molecular Partners has reported significant progress in its DARPin radiotherapeutics pipeline. Their DLL3 radiotherapy candidate, MP0712, is in Phase 1/2a clinical trials with initial data expected soon and comprehensive efficacy data in 2027. The company is also advancing MP0726", "url": "https://www.manilatimes.net/2026/07/06/tmt-newswire/globenewswire/molecular-partners-updates-on-clinical-progress-across-expanding-pipeline-of-darpin-radiotherapeutics/2378733", "source_name": "The Manila Times", "published_at": "2026-07-06T05:04:01", "published_display": "06 Jul 2026 05:04", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Molecular Partners sees first MP0712 data in months, MP0726 imaging in H2", "summary": "Molecular Partners (MOLN) announced significant progress in its Radio-DARPin therapeutics pipeline, with initial data for the MP0712 Phase 1/2a trial expected within months and broader results in 2027. The company also plans first-in-human imaging for MP0726 in H2 2026, two IND f", "url": "https://www.stocktitan.net/news/MOLN/molecular-partners-updates-on-clinical-progress-across-expanding-cydtxoepji5b.html", "source_name": "Stock Titan", "published_at": "2026-07-06T05:03:01", "published_display": "06 Jul 2026 05:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Molecular Partners (MOLN) starts first patient dosing in DLL3 Radio-DARPin MP0712 Phase 1/2a", "summary": "Molecular Partners and Orano Med have announced the first patient dosing in their Phase 1/2a study of MP0712, a DLL3-targeting Radio-DARPin designed for tumors expressing DLL3, such as small cell lung cancer. The study is utilizing a \"matched-pair\" approach, where diagnostic imag", "url": "https://www.stocktitan.net/sec-filings/MOLN/6-k-molecular-partners-ag-current-report-foreign-issuer-354e9b55cfef.html", "source_name": "Stock Titan", "published_at": "2026-07-02T09:40:57", "published_display": "02 Jul 2026 09:40", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Molecular Partners Doses First Patients in Lung Cancer Trial", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/molecular-partners-doses-first-patients-074640408.html", "source_name": "MT Newswires", "published_at": "2026-07-02T07:46:40+00:00", "published_display": "02 Jul 2026 07:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Molecular Partners and Orano Med Announce First Patients Dosed in Phase 1/2a Trial of DLL3 Radio-DARPin MP0712", "summary": "Molecular Partners and Orano Med have announced that the first patients have been dosed in their Phase 1/2a trial for MP0712, a DLL3-targeting Radio-DARPin carrying a 212Pb therapeutic payload. This drug is designed to treat small cell lung cancer and other neuroendocrine tumors.", "url": "https://finance.yahoo.com/healthcare/articles/molecular-partners-orano-med-announce-050000266.html", "source_name": "Market source", "published_at": "2026-07-02T08:00:00", "published_display": "02 Jul 2026 08:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Molecular Partners and Orano Med Dose First Patients in US Phase 1/2a Study of DLL3-Targeting Radio-DARPin MP0712", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxOdEdoWFVxaDVjSTlETGNOWnNLR01KVFlWMWF1aUpldnB4c1NzOHFTeHJ6U25kWUEzcjF5bGVEUVhkbGRkM3M5aXVBaDk2TjVTclk0eTR2TXJidU9lbjQwdkM0S0R1SEhVYnlLbFJMWExfUDgxVUU2U3ZHS3JHdHBmWHpRanROdS1sSmkwTnZvd0c1RDhvLS1wVGdOX2VTSWhQUnNwYnZnc18tdkZKYjA3TGZ0cVpKR0RzbTdMRjF6OFY3X1lfanEzcTFvaER3b21pMUp3dzZtM25QQ2RuMmQzOXVn?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-07-02T05:10:00+00:00", "published_display": "02 Jul 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "First patients dosed in Molecular Partners\u2019 MP0712 DLL3 cancer trial", "summary": "Molecular Partners and Orano Med have announced that the first patients have been dosed in a US multicenter Phase 1/2a trial for their DLL3-targeting, 212Pb-labelled Radio-DARPin MP0712. This program utilizes a matched-pair imaging/therapy design across five actively recruiting U", "url": "https://www.stocktitan.net/news/MOLN/molecular-partners-and-orano-med-announce-first-patients-dosed-in-kkv5lzjlq3sq.html", "source_name": "Stock Titan", "published_at": "2026-07-02T04:40:18", "published_display": "02 Jul 2026 04:40", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Molecular Partners AG \u2013 MUN:6ML", "summary": "This page on TradingView provides financial information specifically the enterprise value to revenue forward for Molecular Partners AG (MUN:6ML). It indicates that the market is currently closed with no trades. The content primarily serves as a data display for financial metrics ", "url": "https://www.tradingview.com/symbols/MUN-6ML/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T04:41:14", "published_display": "30 Jun 2026 04:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "6ML0 Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a price target forecast for Molecular Partners AG Sponsored ADR (6ML0) on the Frankfurt Stock Exchange for 2027. Based on 6 analysts, the current price target is 10.36, with no maximum or minimum estimates provided. It also presents data on EPS and revenue, ", "url": "https://www.tradingview.com/symbols/FWB-6ML0/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-28T10:09:37", "published_display": "28 Jun 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Molecular Partners (MOLN) Slides 3.31% as Stock Tests Key Support Zone - Continuation Pattern Picks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQd0ExejlDeEkwczJURkl4TnRPRzc2QjZ2bDZRYi1BN292MnRvNWl1anR2bjVqWmJwQkJUQTZJZTVqWHJpR1oxMERTT1NFWERWcmxNVnZDd281RFdvbkxfLUxhUmVfdWZoWllqZlkzc0Y1RVBXdFRJOFBlaFZET0hWUTJCZXpyMFEtOE5sbXpzU1RFenFzeDlhSHJWRDJWT1hPeFZPT2dIVmc0ODNCelBR?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-28T07:00:00+00:00", "published_display": "28 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A3CSB5 Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "The article provides a price target and analyst ratings for Molecular Partners AG Sponsored ADR (A3CSB5). According to 6 analysts, the current price target is 10.36. The report also includes disclaimers that it is not investment advice and encourages users to do their own researc", "url": "https://www.tradingview.com/symbols/LS-A3CSB5/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-27T19:40:56", "published_display": "27 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MOLN Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "The article provides a price forecast for Molecular Partners AG (MOLN) with a target of 11.78, based on 6 analysts' 1-year predictions. It includes sections on analyst ratings, EPS, and revenue metrics, while clearly stating that the information provided is not investment advice.", "url": "https://www.tradingview.com/symbols/BOATS-MOLN/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-27T04:10:03", "published_display": "27 Jun 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Molecular Partners AG Actuals & Estimates (SIX:MOLN)", "summary": "This article provides an overview of Molecular Partners AG (SIX:MOLN) stock, including its current price, historical performance, analyst forecasts, and company financials. It details earnings, net income, dividend policy, employee count, and offers guidance for potential investo", "url": "https://www.tradingview.com/symbols/SIX-MOLN/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T07:09:23", "published_display": "26 Jun 2026 07:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Molecular Partners AG Stock 12\u2011Month Price Target Raised to $11.78, Implies 200% Upside", "summary": "The average 12-month price target for Molecular Partners AG stock has been raised to $11.78 from $10.64, according to estimates from six analysts. This updated target suggests a potential upside of approximately 200% from its June 25 closing price. The consensus rating for the st", "url": "https://www.tradingview.com/news/tradingview:1e6351c3abe92:0-molecular-partners-ag-stock-12-month-price-target-raised-to-11-78-implies-200-upside/", "source_name": "TradingView", "published_at": "2026-06-26T05:41:06", "published_display": "26 Jun 2026 05:41", "sentiment": "positive", "sentiment_pct": 93, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Molecular Partners AG (MOLN) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Molecular Partners AG (MOLN) has an earnings forecast score of 8.00, placing it 166th in the Biotechnology & Medical Research industry. Analysts provide an average price target of $13.62, with a \"Buy\" consensus based on 5 analysts. The company's previous quarter EPS was -$0.42, b", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-moln/earnings", "source_name": "TradingKey", "published_at": "2026-06-24T13:10:03", "published_display": "24 Jun 2026 13:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Molecular Partners (MOLN) Holds Steady Near Support Amid Volatile Biotech Sector - Factor Timing", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQV2lKQk83MXlPQ1hYZnBIWW9wS3JLSVNUVVNjYlk0VjY4TE16dGkxRW5ndlhsSEpNV0dnLXd4Nl94cVBsOWR0Q2hhNXJZdFRxQzc0Nlo0NHE1S2lXbVpxMWRfS1ZCVnQtMGplVGQtYnhrVm5rWGs5T29TSHUwNWVwakR2NXZ4SWw5T0tNTFEta1RiS2hZXzcwVE5ydzhXenFiTjVReDgxTDVfdjJZREl3bjR1bW5jaDlWNnIxUQ?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Molecular Partners AG (MOLN) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Molecular Partners AG (MOLN), noting its current valuation score of 7.84, ranking 192 out of 389 in the Biotechnology & Medical Research industry. It highlights the company's current P/E ratio of -1.96, which is significantly below it", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-moln/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T22:09:37", "published_display": "18 Jun 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corporate Revenue Breakdown", "summary": "This article from TradingKey provides a revenue breakdown for Molecular Partners AG (MOLN). It indicates that relevant data for business segments, regional revenue, and profit contribution has not yet been disclosed by the company. The only specific detail mentioned is \"Switzerla", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-moln/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T09:39:50", "published_display": "18 Jun 2026 09:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Molecular Partners AG (MOLN) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of the dividend and stock split history for Molecular Partners AG (MOLN). It notes that the company has not distributed any dividends over the past five years and has no recorded stock split data. The current stock price and market capitalization", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-moln/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T06:39:17", "published_display": "18 Jun 2026 06:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Molecular Partners AG (MOLN) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the major shareholders and institutional holdings of Molecular Partners AG (MOLN). It identifies Suvretta Capital Management, LLC, BVF Partners L.P., and SmartHarvest Portfolios, LLC as key shareholders and outlines their proportions. The report also provides", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-moln/ownership", "source_name": "TradingKey", "published_at": "2026-06-18T00:39:17", "published_display": "18 Jun 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Molecular Partners AG (MOLN) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Molecular Partners AG (MOLN), highlighting its current price momentum score of 6.49 within the Biotechnology & Medical Research industry. It identifies the stock trading between a resistance level of $4.29 and a support level of $3.60", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-moln/technical", "source_name": "TradingKey", "published_at": "2026-06-17T10:11:46", "published_display": "17 Jun 2026 10:11", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Molecular Partners AG (MOLN) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "This article provides a risk assessment for Molecular Partners AG (MOLN), highlighting its current risk score of 2.80 within the Biotechnology & Medical Research industry and a beta value of 1.07. It details various risk metrics including volatility, maximum drawdown, and return-", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-moln/risk-assesment", "source_name": "TradingKey", "published_at": "2026-06-17T09:11:47", "published_display": "17 Jun 2026 09:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Molecular Partners Holds Presentations at ASCO and SNMMI 2026 on DLL3-Targeting Radio-DARPin MP0712, Now Dosing Patients in Phase 1", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/molecular-partners-holds-presentations-asco-120000592.html", "source_name": "GlobeNewswire", "published_at": "2026-05-30T12:00:00+00:00", "published_display": "30 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Molecular Partners AG to Present MP0712 Phase 1/2a Study Findings at 2026 ASCO and SNMMI Annual Meetings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxPcEZUVGhnd0kycXlfZFRjbDI5dGFWZ0c3bTBkR19QaHNGSmJ3NGtweFhBR0xTUDRSRnY2YklCV2FZR202Y3RUM0pPVGtGaWJWUU5RWGdoQ21QMW1VS19DQVAwZWFPR3NtVklvTFpBdGEtMEc2b2NOdDU0aDBLRzlhTTRHRWRIdkR1Nk1ra2NtY3ZrX3lsNDVEWmZfSndObUNzcWdaenJKMERELTV1aHRPSVExN2R6MjhWVWZoV2ZtLThQdmNkZkR3cjhQRV85dzdjWVd1dEln?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-30T07:00:00+00:00", "published_display": "30 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Molecular Partners to Present at TD Cowen\u2019s 7th Annual Oncology Innovation Summit", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/molecular-partners-present-td-cowen-200000036.html", "source_name": "GlobeNewswire", "published_at": "2026-05-26T20:00:00+00:00", "published_display": "26 May 2026 20:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Molecular Partners and Orano Med Strengthen Agreement to Co-Develop 212Pb-Based Radio-DARPin Therapeutics", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPQkEyZHBhWHkwSVVyZEdNcW5sQUxoSWtZWnNZNEFJYjFTal9LRGNQWEQ3b2RrbGowX0ZRZDVmTEhWZERKdmo5UndvYmkydUh1dTBSZDUxNmdhc3Y3S2Y4Snp6Qkhid0l1QTJGM2w3OVd1ZEg1aWlNSEZkcElIcjU0b2RSN3h4ZURoeDZTZEs4VGgyM2t5WTJMLXNMR0p6alB1eTJuNDhicDdxWFVWLXJ5dUxmYW1fLS1aXzlqSU40QQ?oc=5", "source_name": "Stock Titan", "published_at": "2024-10-21T07:00:00+00:00", "published_display": "21 Oct 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MOLECULAR PARTNERS AG (MOLN) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Molecular Partners AG (MOLN)", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-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?oc=5", "source_name": "TMX Newsfile", "published_at": "2022-09-01T21:09:13+00:00", "published_display": "01 Sep 2022 21:09", "sentiment": "negative", "sentiment_pct": 34, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MOLECULAR PARTNERS (MOLN) Stock News & Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiTkFVX3lxTE5rbndzNWlCR0ptZGtYYUhpNjRzVTVWZXBLWWJOOW5pSDJONHBhSVU4cmhJWXJCQlRETUpGZXh4TW5PTlhlU3Q3MElyQy1qdw?oc=5", "source_name": "Stock Titan", "published_at": "2021-07-08T05:00:56+00:00", "published_display": "08 Jul 2021 05:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Molecular Partners Doses First Patients in Phase 2 Study of Biliary Tract Cancer Therapy", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/molecular-partners-doses-first-patients-073420686.html", "source_name": "MT Newswires", "published_at": "2026-07-16T07:34:20+00:00", "published_display": "16 Jul 2026 07:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Molecular Partners Announces Clinical Progress in Phase 2 TACTIC Combination Trial of MP0317 for Patients with Cholangiocarcinoma", "summary": "Molecular Partners has announced clinical progress in its Phase 2 TACTIC trial for MP0317, a drug for advanced biliary tract carcinoma (cholangiocarcinoma). The randomized study, combining MP0317 with chemoimmunotherapy, is actively recruiting patients across nine sites in France", "url": "https://www.manilatimes.net/2026/07/16/tmt-newswire/globenewswire/molecular-partners-announces-clinical-progress-in-phase-2-tactic-combination-trial-of-mp0317-for-patients-with-cholangiocarcinoma/2385574", "source_name": "The Manila Times", "published_at": "2026-07-16T05:11:23", "published_display": "16 Jul 2026 05:11", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Molecular Partners Showcases Bispecific Radio-DARPins at Gordon Research Conference", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/molecular-partners-showcases-bispecific-radio-050000390.html", "source_name": "GlobeNewswire", "published_at": "2026-07-15T05:00:00+00:00", "published_display": "15 Jul 2026 05:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Molecular Partners Highlights Bispecific Radio-DARPin Approach to Target Tumor Heterogeneity in Cancer", "summary": "Molecular Partners presented its bispecific Radio-DARPin approach to target tumor heterogeneity in cancer at the Gordon Research Conference. This innovative method aims to enhance radioligand therapy (RLT) by simultaneously engaging multiple tumor markers, thereby improving treat", "url": "https://www.quiverquant.com/news/Molecular+Partners+Highlights+Bispecific+Radio-DARPin+Approach+to+Target+Tumor+Heterogeneity+in+Cancer", "source_name": "Quiver Quantitative", "published_at": "2026-07-15T04:43:54", "published_display": "15 Jul 2026 04:43", "sentiment": "positive", "sentiment_pct": 82, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Molecular Partners Develops Two-Target Cancer Radiopharmaceuticals", "summary": "Molecular Partners presented new data on its bispecific and multispecific Radio-DARPins at the Gordon Research Conference on Radionuclide Theranostics for the Management of Cancer. The company is developing these Radio-DARPins to address tumor heterogeneity and engage multiple ca", "url": "https://www.stocktitan.net/news/MOLN/molecular-partners-showcases-bispecific-radio-dar-pins-at-gordon-6qs9gd3l9t6w.html", "source_name": "Stock Titan", "published_at": "2026-07-15T04:43:54", "published_display": "15 Jul 2026 04:43", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "European Penny Stocks To Watch In July 2026", "summary": "This article identifies three European penny stocks (Piquadro, GiG Software, and Molecular Partners) with potential for investors seeking growth opportunities beyond mainstream markets. It highlights their financial health, market performance, and strategic initiatives, noting bo", "url": "https://simplywall.st/stocks/ch/pharmaceuticals-biotech/vtx-moln/molecular-partners-shares/news/european-penny-stocks-to-watch-in-july-2026-1/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-09T05:39:59", "published_display": "09 Jul 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Molecular Partners (MOLN) Gains 2.25% as Buyers Test Resistance Near $4.29 - AD Line Divergence", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxPVXJVTFY0SzJWWnRJS2xwd01OMUhlUy1iSnc3QTRaOFhyQkljTG1idXhSSU52TGp2cEJPSVpfMHU5RFdxTHdYcTgwb2VKWkk2WGFmdDctTm94V1dZY0N5dkFTTWZKUUE1dUdiRGpfR2UwLVE5bGVnVnBBLU5RZ0loc2tjZHJpZ2c1aTZPTExjYXQxblF0MUF1SVpXM193cVQ1MHhIRXJVbXdOU3E1Vmo4clZB?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-08T01:41:33+00:00", "published_display": "08 Jul 2026 01:41", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Molecular Partners (NASDAQ: MOLN) details progress in Radio-DARPin cancer pipeline", "summary": "Molecular Partners (MOLN) provided an update on its Radio-DARPin pipeline for cancer treatment, announcing that its lead candidate, MP0712, is in an ongoing Phase 1/2a trial with initial data expected soon and comprehensive results in 2027. The company also highlighted a compassi", "url": "https://www.stocktitan.net/sec-filings/MOLN/6-k-molecular-partners-ag-current-report-foreign-issuer-cdb1a8ba4a33.html", "source_name": "Stock Titan", "published_at": "2026-07-07T10:09:30", "published_display": "07 Jul 2026 10:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Molecular Partners advances MP0712 cancer trial", "summary": "Molecular Partners has reported pipeline progress in its radiopharmaceutical programs, including active patient dosing in a Phase 1/2a trial for MP0712, targeting DLL3-positive small cell lung cancer and neuroendocrine tumors. Initial clinical data for MP0712 is anticipated in th", "url": "https://grafa.com/en/news/united-states/molecular-partners-radio-darpin-mp0712-clinical-trial", "source_name": "grafa.com", "published_at": "2026-07-06T13:11:03", "published_display": "06 Jul 2026 13:11", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Molecular Partners stock rating on trial progress By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxPVy1COEpJTTJWS0lDTGhTcUhaUy05RVBtZ3dlYWd1cTRrRl9ZTUs4NUdLUjVqeWo0ZmlvaVkzMG1sQ2NfR3hnalFESEhOM2d1eWFfUWZjbk9SbEZtSWNsbHg3dXNRVFBia0FyRVE2em9DTm5DR2wyVkhId05zUUpxMFdKUElyc05uRklMREs1dDhUeUtkSkthbEh2ZFhxZzZHTnJXc0lTem96dDR0M2VTeEthVTZ5Z3pMMDAxazlROXR2bVM0ZmpfbFBHcTBHUjlX?oc=5", "source_name": "Investing.com South Africa", "published_at": "2026-07-06T12:03:39+00:00", "published_display": "06 Jul 2026 12:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Molecular Partners stock rating on trial progress", "summary": "H.C. Wainwright has reiterated a Buy rating and a $13.00 price target for Molecular Partners (NASDAQ:MOLN) following progress in its clinical trials. The company recently announced the first patient dosing in a Phase 1/2a trial for MP0712, a DLL3-targeted Radio-DARPin for small c", "url": "https://www.investing.com/news/analyst-ratings/hc-wainwright-reiterates-molecular-partners-stock-rating-on-trial-progress-93CH-4776192", "source_name": "Investing.com", "published_at": "2026-07-06T12:11:04", "published_display": "06 Jul 2026 12:11", "sentiment": "positive", "sentiment_pct": 76, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Molecular Partners Makes Progress on Radiotherapy Cancer Candidates", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/molecular-partners-makes-progress-radiotherapy-095132431.html", "source_name": "MT Newswires", "published_at": "2026-07-06T09:51:32+00:00", "published_display": "06 Jul 2026 09:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Molecular Partners Updates on Clinical Progress Across Expanding Pipeline of DARPin Radiotherapeutics", "summary": "Molecular Partners has reported significant progress in its DARPin radiotherapeutics pipeline. Their DLL3 radiotherapy candidate, MP0712, is in Phase 1/2a clinical trials with initial data expected soon and comprehensive efficacy data in 2027. The company is also advancing MP0726", "url": "https://www.manilatimes.net/2026/07/06/tmt-newswire/globenewswire/molecular-partners-updates-on-clinical-progress-across-expanding-pipeline-of-darpin-radiotherapeutics/2378733", "source_name": "The Manila Times", "published_at": "2026-07-06T05:04:01", "published_display": "06 Jul 2026 05:04", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Molecular Partners sees first MP0712 data in months, MP0726 imaging in H2", "summary": "Molecular Partners (MOLN) announced significant progress in its Radio-DARPin therapeutics pipeline, with initial data for the MP0712 Phase 1/2a trial expected within months and broader results in 2027. The company also plans first-in-human imaging for MP0726 in H2 2026, two IND f", "url": "https://www.stocktitan.net/news/MOLN/molecular-partners-updates-on-clinical-progress-across-expanding-cydtxoepji5b.html", "source_name": "Stock Titan", "published_at": "2026-07-06T05:03:01", "published_display": "06 Jul 2026 05:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Molecular Partners (MOLN) starts first patient dosing in DLL3 Radio-DARPin MP0712 Phase 1/2a", "summary": "Molecular Partners and Orano Med have announced the first patient dosing in their Phase 1/2a study of MP0712, a DLL3-targeting Radio-DARPin designed for tumors expressing DLL3, such as small cell lung cancer. The study is utilizing a \"matched-pair\" approach, where diagnostic imag", "url": "https://www.stocktitan.net/sec-filings/MOLN/6-k-molecular-partners-ag-current-report-foreign-issuer-354e9b55cfef.html", "source_name": "Stock Titan", "published_at": "2026-07-02T09:40:57", "published_display": "02 Jul 2026 09:40", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Molecular Partners Doses First Patients in Lung Cancer Trial", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/molecular-partners-doses-first-patients-074640408.html", "source_name": "MT Newswires", "published_at": "2026-07-02T07:46:40+00:00", "published_display": "02 Jul 2026 07:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Molecular Partners and Orano Med Announce First Patients Dosed in Phase 1/2a Trial of DLL3 Radio-DARPin MP0712", "summary": "Molecular Partners and Orano Med have announced that the first patients have been dosed in their Phase 1/2a trial for MP0712, a DLL3-targeting Radio-DARPin carrying a 212Pb therapeutic payload. This drug is designed to treat small cell lung cancer and other neuroendocrine tumors.", "url": "https://finance.yahoo.com/healthcare/articles/molecular-partners-orano-med-announce-050000266.html", "source_name": "Market source", "published_at": "2026-07-02T08:00:00", "published_display": "02 Jul 2026 08:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Molecular Partners and Orano Med Dose First Patients in US Phase 1/2a Study of DLL3-Targeting Radio-DARPin MP0712", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxOdEdoWFVxaDVjSTlETGNOWnNLR01KVFlWMWF1aUpldnB4c1NzOHFTeHJ6U25kWUEzcjF5bGVEUVhkbGRkM3M5aXVBaDk2TjVTclk0eTR2TXJidU9lbjQwdkM0S0R1SEhVYnlLbFJMWExfUDgxVUU2U3ZHS3JHdHBmWHpRanROdS1sSmkwTnZvd0c1RDhvLS1wVGdOX2VTSWhQUnNwYnZnc18tdkZKYjA3TGZ0cVpKR0RzbTdMRjF6OFY3X1lfanEzcTFvaER3b21pMUp3dzZtM25QQ2RuMmQzOXVn?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-07-02T05:10:00+00:00", "published_display": "02 Jul 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "First patients dosed in Molecular Partners\u2019 MP0712 DLL3 cancer trial", "summary": "Molecular Partners and Orano Med have announced that the first patients have been dosed in a US multicenter Phase 1/2a trial for their DLL3-targeting, 212Pb-labelled Radio-DARPin MP0712. This program utilizes a matched-pair imaging/therapy design across five actively recruiting U", "url": "https://www.stocktitan.net/news/MOLN/molecular-partners-and-orano-med-announce-first-patients-dosed-in-kkv5lzjlq3sq.html", "source_name": "Stock Titan", "published_at": "2026-07-02T04:40:18", "published_display": "02 Jul 2026 04:40", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Molecular Partners AG \u2013 MUN:6ML", "summary": "This page on TradingView provides financial information specifically the enterprise value to revenue forward for Molecular Partners AG (MUN:6ML). It indicates that the market is currently closed with no trades. The content primarily serves as a data display for financial metrics ", "url": "https://www.tradingview.com/symbols/MUN-6ML/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T04:41:14", "published_display": "30 Jun 2026 04:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "6ML0 Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a price target forecast for Molecular Partners AG Sponsored ADR (6ML0) on the Frankfurt Stock Exchange for 2027. Based on 6 analysts, the current price target is 10.36, with no maximum or minimum estimates provided. It also presents data on EPS and revenue, ", "url": "https://www.tradingview.com/symbols/FWB-6ML0/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-28T10:09:37", "published_display": "28 Jun 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Molecular Partners (MOLN) Slides 3.31% as Stock Tests Key Support Zone - Continuation Pattern Picks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQd0ExejlDeEkwczJURkl4TnRPRzc2QjZ2bDZRYi1BN292MnRvNWl1anR2bjVqWmJwQkJUQTZJZTVqWHJpR1oxMERTT1NFWERWcmxNVnZDd281RFdvbkxfLUxhUmVfdWZoWllqZlkzc0Y1RVBXdFRJOFBlaFZET0hWUTJCZXpyMFEtOE5sbXpzU1RFenFzeDlhSHJWRDJWT1hPeFZPT2dIVmc0ODNCelBR?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-28T07:00:00+00:00", "published_display": "28 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A3CSB5 Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "The article provides a price target and analyst ratings for Molecular Partners AG Sponsored ADR (A3CSB5). According to 6 analysts, the current price target is 10.36. The report also includes disclaimers that it is not investment advice and encourages users to do their own researc", "url": "https://www.tradingview.com/symbols/LS-A3CSB5/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-27T19:40:56", "published_display": "27 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MOLN Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "The article provides a price forecast for Molecular Partners AG (MOLN) with a target of 11.78, based on 6 analysts' 1-year predictions. It includes sections on analyst ratings, EPS, and revenue metrics, while clearly stating that the information provided is not investment advice.", "url": "https://www.tradingview.com/symbols/BOATS-MOLN/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-27T04:10:03", "published_display": "27 Jun 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Molecular Partners AG Actuals & Estimates (SIX:MOLN)", "summary": "This article provides an overview of Molecular Partners AG (SIX:MOLN) stock, including its current price, historical performance, analyst forecasts, and company financials. It details earnings, net income, dividend policy, employee count, and offers guidance for potential investo", "url": "https://www.tradingview.com/symbols/SIX-MOLN/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T07:09:23", "published_display": "26 Jun 2026 07:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Molecular Partners AG Stock 12\u2011Month Price Target Raised to $11.78, Implies 200% Upside", "summary": "The average 12-month price target for Molecular Partners AG stock has been raised to $11.78 from $10.64, according to estimates from six analysts. This updated target suggests a potential upside of approximately 200% from its June 25 closing price. The consensus rating for the st", "url": "https://www.tradingview.com/news/tradingview:1e6351c3abe92:0-molecular-partners-ag-stock-12-month-price-target-raised-to-11-78-implies-200-upside/", "source_name": "TradingView", "published_at": "2026-06-26T05:41:06", "published_display": "26 Jun 2026 05:41", "sentiment": "positive", "sentiment_pct": 93, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Molecular Partners AG (MOLN) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Molecular Partners AG (MOLN) has an earnings forecast score of 8.00, placing it 166th in the Biotechnology & Medical Research industry. Analysts provide an average price target of $13.62, with a \"Buy\" consensus based on 5 analysts. The company's previous quarter EPS was -$0.42, b", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-moln/earnings", "source_name": "TradingKey", "published_at": "2026-06-24T13:10:03", "published_display": "24 Jun 2026 13:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Molecular Partners (MOLN) Holds Steady Near Support Amid Volatile Biotech Sector - Factor Timing", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQV2lKQk83MXlPQ1hYZnBIWW9wS3JLSVNUVVNjYlk0VjY4TE16dGkxRW5ndlhsSEpNV0dnLXd4Nl94cVBsOWR0Q2hhNXJZdFRxQzc0Nlo0NHE1S2lXbVpxMWRfS1ZCVnQtMGplVGQtYnhrVm5rWGs5T29TSHUwNWVwakR2NXZ4SWw5T0tNTFEta1RiS2hZXzcwVE5ydzhXenFiTjVReDgxTDVfdjJZREl3bjR1bW5jaDlWNnIxUQ?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Molecular Partners AG (MOLN) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Molecular Partners AG (MOLN), noting its current valuation score of 7.84, ranking 192 out of 389 in the Biotechnology & Medical Research industry. It highlights the company's current P/E ratio of -1.96, which is significantly below it", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-moln/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T22:09:37", "published_display": "18 Jun 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corporate Revenue Breakdown", "summary": "This article from TradingKey provides a revenue breakdown for Molecular Partners AG (MOLN). It indicates that relevant data for business segments, regional revenue, and profit contribution has not yet been disclosed by the company. The only specific detail mentioned is \"Switzerla", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-moln/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T09:39:50", "published_display": "18 Jun 2026 09:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Molecular Partners AG (MOLN) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of the dividend and stock split history for Molecular Partners AG (MOLN). It notes that the company has not distributed any dividends over the past five years and has no recorded stock split data. The current stock price and market capitalization", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-moln/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T06:39:17", "published_display": "18 Jun 2026 06:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Molecular Partners AG (MOLN) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the major shareholders and institutional holdings of Molecular Partners AG (MOLN). It identifies Suvretta Capital Management, LLC, BVF Partners L.P., and SmartHarvest Portfolios, LLC as key shareholders and outlines their proportions. The report also provides", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-moln/ownership", "source_name": "TradingKey", "published_at": "2026-06-18T00:39:17", "published_display": "18 Jun 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Molecular Partners AG (MOLN) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Molecular Partners AG (MOLN), highlighting its current price momentum score of 6.49 within the Biotechnology & Medical Research industry. It identifies the stock trading between a resistance level of $4.29 and a support level of $3.60", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-moln/technical", "source_name": "TradingKey", "published_at": "2026-06-17T10:11:46", "published_display": "17 Jun 2026 10:11", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Molecular Partners AG (MOLN) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "This article provides a risk assessment for Molecular Partners AG (MOLN), highlighting its current risk score of 2.80 within the Biotechnology & Medical Research industry and a beta value of 1.07. It details various risk metrics including volatility, maximum drawdown, and return-", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-moln/risk-assesment", "source_name": "TradingKey", "published_at": "2026-06-17T09:11:47", "published_display": "17 Jun 2026 09:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Molecular Partners Holds Presentations at ASCO and SNMMI 2026 on DLL3-Targeting Radio-DARPin MP0712, Now Dosing Patients in Phase 1", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/molecular-partners-holds-presentations-asco-120000592.html", "source_name": "GlobeNewswire", "published_at": "2026-05-30T12:00:00+00:00", "published_display": "30 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Molecular Partners AG to Present MP0712 Phase 1/2a Study Findings at 2026 ASCO and SNMMI Annual Meetings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxPcEZUVGhnd0kycXlfZFRjbDI5dGFWZ0c3bTBkR19QaHNGSmJ3NGtweFhBR0xTUDRSRnY2YklCV2FZR202Y3RUM0pPVGtGaWJWUU5RWGdoQ21QMW1VS19DQVAwZWFPR3NtVklvTFpBdGEtMEc2b2NOdDU0aDBLRzlhTTRHRWRIdkR1Nk1ra2NtY3ZrX3lsNDVEWmZfSndObUNzcWdaenJKMERELTV1aHRPSVExN2R6MjhWVWZoV2ZtLThQdmNkZkR3cjhQRV85dzdjWVd1dEln?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-30T07:00:00+00:00", "published_display": "30 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Molecular Partners to Present at TD Cowen\u2019s 7th Annual Oncology Innovation Summit", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/molecular-partners-present-td-cowen-200000036.html", "source_name": "GlobeNewswire", "published_at": "2026-05-26T20:00:00+00:00", "published_display": "26 May 2026 20:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Molecular Partners and Orano Med Strengthen Agreement to Co-Develop 212Pb-Based Radio-DARPin Therapeutics", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPQkEyZHBhWHkwSVVyZEdNcW5sQUxoSWtZWnNZNEFJYjFTal9LRGNQWEQ3b2RrbGowX0ZRZDVmTEhWZERKdmo5UndvYmkydUh1dTBSZDUxNmdhc3Y3S2Y4Snp6Qkhid0l1QTJGM2w3OVd1ZEg1aWlNSEZkcElIcjU0b2RSN3h4ZURoeDZTZEs4VGgyM2t5WTJMLXNMR0p6alB1eTJuNDhicDdxWFVWLXJ5dUxmYW1fLS1aXzlqSU40QQ?oc=5", "source_name": "Stock Titan", "published_at": "2024-10-21T07:00:00+00:00", "published_display": "21 Oct 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MOLECULAR PARTNERS AG (MOLN) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Molecular Partners AG (MOLN)", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-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?oc=5", "source_name": "TMX Newsfile", "published_at": "2022-09-01T21:09:13+00:00", "published_display": "01 Sep 2022 21:09", "sentiment": "negative", "sentiment_pct": 34, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MOLECULAR PARTNERS (MOLN) Stock News & Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiTkFVX3lxTE5rbndzNWlCR0ptZGtYYUhpNjRzVTVWZXBLWWJOOW5pSDJONHBhSVU4cmhJWXJCQlRETUpGZXh4TW5PTlhlU3Q3MElyQy1qdw?oc=5", "source_name": "Stock Titan", "published_at": "2021-07-08T05:00:56+00:00", "published_display": "08 Jul 2021 05:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 87, "total_relevant": 48, "sentiment_summary": {"positive": 14, "negative": 3, "neutral": 31, "score": 58, "total": 48, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 79, "events": [{"event": "general", "label": "Market update", "weight": 13.75, "count": 25}, {"event": "earnings", "label": "Earnings", "weight": 7.7, "count": 16}, {"event": "analyst", "label": "Analyst action", "weight": 2.75, "count": 5}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}], "positive_events": 14, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 4.02, "latest_week": "2026-07-10", "one_week_move": 1.1, "four_week_move": -2.1, "twelve_week_move": -4.3, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.539241, "market_dynamics_buy_signal": false, "relative_strength": -15.89069, "fair_value_gap": -12.6, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 47.6613, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+1.1% over one week, -2.1% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 67, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 7}, {"label": "TradingView", "count": 7}, {"label": "TradingKey", "count": 7}, {"label": "Market source", "count": 6}, {"label": "MT Newswires", "count": 3}, {"label": "GlobeNewswire", "count": 3}, {"label": "Quiver Quantitative", "count": 3}, {"label": "dars.gov.et", "count": 3}], "tiers": [{"label": "Direct company coverage", "count": 40}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 25}, {"label": "Earnings", "count": 16}, {"label": "Analyst action", "count": 5}, {"label": "Capital return", "count": 1}, {"label": "Regulatory and legal", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "58/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "79/100 classification confidence."}, {"label": "Company focus", "value": "40", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+1.1% over one week, -2.1% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Molecular Partners Doses First Patients in Phase 2 Study of Biliary Tract Cancer Therapy"}], "updated_at": "2026-07-16T13:32:27.006784+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}